Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals

Sian Faustini, Adrian Shields, Gemma Banham, Nadezhda Wall, Saly Al-Taei, Chloe Tanner, Zahra Ahmed, Elena Efstathiou, Neal Townsend, Margaret Goodall, Tim Plant, Marisol Perez-Toledo, Aleksandra Jasiulewicz, Ruth Price, James McLaughlin, John Farnan, Julie Moore, Louise Robertson, Andrew Nesbit, Grace CurryAmy Black, Adam Cunningham, Lorraine Harper, Tara Moore, Mark Drayson, Alex Richter

Research output: Contribution to journalLetterpeer-review

14 Citations (Scopus)

Abstract

Highlights
• IgG anti-SARS-CoV-2 Omicron spike glycoprotein antibodies were detected in 100% of health care workers, a real world population attending general practice for vaccination and haemodialysis patients 4 weeks after a third SARS-CoV-2 vaccine dose (Pfizer-BioNtech 162b2).
• Against both Delta and Omicron variants, antibody levels were higher in the cohort who had previously received two doses of AstraZeneca ChAdOx1 nCoV-19 vaccine than two doses of Pfizer-BioNtech 162b2.
• Prior to this third vaccine dose and 6 months post second vaccine dose, there was evidence of significant waning of antibody reactivity against Delta and Omicron variants of concern, particularly in individuals initially receiving two doses of AstraZeneca ChAdOx1 nCoV-19.
Original languageEnglish
Pages (from-to)579-613
Number of pages35
JournalJournal of Infection
Volume84
Issue number4
Early online date10 Jan 2022
DOIs
Publication statusPublished (in print/issue) - 8 Apr 2022

Bibliographical note

Funding Information:
We thank the staff and patients that have kindly volunteered for this study. Thanks also to Abingdon Health for the Wuhan and Delta antigens. The authors would like to acknowledge the COVID-HD Birmingham Study Group and PITCH consortium that have enabled this work, the staff of the Clinical Immunology Service, managed by Tim Plant, who helped process the healthcare worker and haemodialysis samples and Dr. Margaret Goodall for her expertise in antibody production and assay development. The authors would also like to acknowledge the National Institute for Health Research (NIHR)/Wellcome Trust Birmingham Clinical Research Facility and University Hospitals Birmingham Research and Development team, in particular the research nurses that enabled the sample consent and sample collection including Mary Dutton, Lesley Fifer, Sinead White, Natalie Walmsley-Allen, Lucy Atchinson-Jones, Kulli Kuningas, Margaret Carmody, Rani Maria Joseph, Christopher McGhee, Shannon Page and Michelle Bates. Also, The Ulster Pandemic Study team. The COCO/PITCH healthcare worker cohort was funded by the United Kingdom Department of Health and Social Care and United Kingdom Research and Innovation COVID-19 Rapid Response Rolling Call as part of the PITCH Consortium. The HD cohort was funded by the United Kingdom Research and Innovation COVID-19 Rapid Response Rolling Call. The COVID-HD Birmingham Study Group include Claire Backhouse, Anna Casey, Lynsey Dunbar, Beena Emmanuel, Megan Fahy, Alexandra Godlee, Paul Moss, Peter Nightingale, Liz Ratcliffe, Stephanie Stringer, Matthew Tabinor, Sian Faustini, Adam Cunningham, Alex Richter, Lorraine Harper. The PITCH study Group include Susanna Dunachie, Paul Klenerman, Lance Turtle, Thushan de Silva, Christopher Duncan, Rebecca Payne, Alex Richter, Ellie Barnes, Miles Carroll, Alexandra Deeks, Christina Dold.

Funding Information:
We thank the staff and patients that have kindly volunteered for this study. Thanks also to Abingdon Health for the Wuhan and Delta antigens. The authors would like to acknowledge the COVID-HD Birmingham Study Group and PITCH consortium that have enabled this work, the staff of the Clinical Immunology Service, managed by Tim Plant, who helped process the healthcare worker and haemodialysis samples and Dr. Margaret Goodall for her expertise in antibody production and assay development. The authors would also like to acknowledge the National Institute for Health Research (NIHR)/Wellcome Trust Birmingham Clinical Research Facility and University Hospitals Birmingham Research and Development team, in particular the research nurses that enabled the sample consent and sample collection including Mary Dutton, Lesley Fifer, Sinead White, Natalie Walmsley-Allen, Lucy Atchinson-Jones, Kulli Kuningas, Margaret Carmody, Rani Maria Joseph, Christopher McGhee, Shannon Page and Michelle Bates. Also, The Ulster Pandemic Study team. The COCO/PITCH healthcare worker cohort was funded by the United Kingdom Department of Health and Social Care and United Kingdom Research and Innovation COVID-19 Rapid Response Rolling Call as part of the PITCH Consortium. The HD cohort was funded by the United Kingdom Research and Innovation COVID-19 Rapid Response Rolling Call. The COVID-HD Birmingham Study Group include Claire Backhouse, Anna Casey, Lynsey Dunbar, Beena Emmanuel, Megan Fahy, Alexandra Godlee, Paul Moss, Peter Nightingale, Liz Ratcliffe, Stephanie Stringer, Matthew Tabinor, Sian Faustini, Adam Cunningham, Alex Richter, Lorraine Harper. The PITCH study Group include Susanna Dunachie, Paul Klenerman, Lance Turtle, Thushan de Silva, Christopher Duncan, Rebecca Payne, Alex Richter, Ellie Barnes, Miles Carroll, Alexandra Deeks, Christina Dold.

Keywords

  • COVID-19
  • SARS-CoV-2
  • Haemodialysis
  • Chronic kidney disease
  • Vaccination
  • antibody response
  • Variants of Concern
  • Cross reactivity
  • Delta
  • Omicron
  • vaccination

Fingerprint

Dive into the research topics of 'Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals'. Together they form a unique fingerprint.

Cite this